Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsGrowth Hormone Peptides

Injectable Growth Hormone Peptides Eptifibatide Raw Steroid Powders CAS 148031-34-9

Injectable Growth Hormone Peptides Eptifibatide Raw Steroid Powders CAS 148031-34-9

    • Injectable Growth Hormone Peptides Eptifibatide Raw Steroid Powders CAS 148031-34-9
    • Injectable Growth Hormone Peptides Eptifibatide Raw Steroid Powders CAS 148031-34-9
  • Injectable Growth Hormone Peptides Eptifibatide Raw Steroid Powders CAS 148031-34-9

    Product Details:

    Place of Origin: China
    Brand Name: Kafen
    Certification: GMP,ISO,UKAS
    Model Number: 148031-34-9

    Payment & Shipping Terms:

    Minimum Order Quantity: As your required.
    Price: Negotiable
    Packaging Details: According to your requirements.
    Delivery Time: Within 24 hours after receiving your payment.
    Payment Terms: Western Union,Money Gram,Bank Transfer,Bitcoin
    Supply Ability: 1000KG/Month
    Contact Now
    Detailed Product Description
    Product Name: Eptifibatide CAS: 148031-34-9
    Assay: 98% Appearance: White Slightly Yellwish Powder
    MF: C35H49N11O9S2 MW: 831.96

    Basic Info.

     

    Eptifibatide
    Sequence: Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2
    Cas No.: 148031-34-9
    Molecular Formula: C35H49N11O9S2
    Molecular Weight: 831.96
    Appearance: White slightly yellwish powder
    Specific Rotation[20/D]: -75.0~-95.0°(C=1,1%HAc)
    Amino Acids composition: ± 10%
    Peptide Purity (By HPLC): >98% by area integration
    Related Substance (By HPLC): Total Impurities (%)<2.0%;Largest Single Impurity (%)< 1.0%
    Water Content (Karl Fischer): <8.0%
    Peptide Content(N determination): >80%
    Acetate Content: <15%
    IR spectrum: in accordance
    Grade : Pharmaceutical Grade
    Storage: Closed, below 2 ~ 8ºC preservation
    Usage : Platelet glycoprotein receptor antagonist model, the third generation of antiplatelet drugs. For acute coronary syndrome (including unstable angina or non Q wave myocardial infarction) or percutaneous coronary interventional therapy (including angioplasty or atheromatous plaque excision).


    Description:

     

    Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
    Integrilin is sold in two strengths, globally: vials containing 2 mg/ml (20 mg totally) and 0.75 mg/ml (75 mg totally).


    Application:

     

    Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).

     

    The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.

     

    Human growth hormone:

     

    GHRP-6 5mg/vial GHRP-2 5mg/vial Ipamorelin 5mg/vial Ipamorelin 5mg/vial
    CJC-1295 with DAC 2mg/vial CJC-1295 W/O DAC 2mg/vial MT-2 10mg/vial MT-1 10mg/vial
    PEG-MGF (IGF 1EC)2mg/vial PEG-MGF 2mg/vial HGH FAG 176-191 5mg/vial FAG 176-195 2mg/vial
    Hexarelin 5mg/vial Hexarelin 2mg/vial Thymosin bate 4 2mg/vial Sermorelin 2mg/vial
    PT-141 10mg/vial DSIP 5mg/vial DSIP 1mg/vial Selank 5mg/vial
    Selank 2mg/vial Oxytocin 2mg/vial Gonadorelin 2mg/vial Triptorelin 100mcg/vial
    GHRP 2mg/vial Tesamorelin 2mg/vial BPC 157 5mg/vial Follistatin 1mg/vial

     

    Indications:


    Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI). The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide. The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.


    Contraindications and precautions:


    1. Thrombocytopenia : The drug is contraindicated in patients with platelet counts of less than 100,000 per μl because no clinical experience exists regarding such patients.

    2. Renal insufficiency : Eptifibatide undergoes renal elimination. In such patients with renal insufficiency where a glycoprotein IIb/IIIa inhibitor is likely to provide benefit, Abciximab (trade name: Reopro) is an alternative medication.

    3. Current bleeding tendencies or abnormally prolonged coagulation parameters observed within 30 days before starting therapy with eptifibatide is intended.

    4. Coagulation parameters such as ACT, aPTT, TT, and PT should be followed closely during therapy and afterwards. Allergy to eptifibatide and/or other ingredients. Severe, uncontrolled hypertension.

    5. Pregnancy : No experience exists. Pregnant patients should be treated only when clearly needed.

    6. Lactation : No human data exists. Breast-feeding should be avoided during treatment in order to prevent damage to the newborn.

    7. Geriatric patients : No differences in side effects compared with younger patients have been seen. Nevertheless, geriatric patients should be very closely observed for bleeding and other side-effects.

    8. Pediatric patients : Eptifibatide is not indicated in patients below 18 years of age, because no experience exists

     

     

    Company Introduction:

     

    (1) High Quality:Kafen Biotech is a steroids manufacturer with its own lab and factory.
    The purity of our product is tested by our quality department before it is shipped to our clients. Mostly steroids are 99% purity and approved by SGS,CTI and ITS.

     

    (2) Favorable Price: Our price meets international market performance and we give the best doiscounted price for our new customers and promotioned price for our regular customers.

     

    (3) Safe Fast Delivery: After receiving your payment,we will have professional package team to arrange your parcel within 12 hours.We can guarantee every goods can be successfully deliveried.

     

    (4) Available Shipment Way: EMS,HongKong Post,DHL,TNT,UPS,FedEx,Registered Mail,Air Express,Sea Vessel etc.

     

    (5) After-Sale Service: We can offer you good service after you place an order.At the same time,we can offer you some homebrew recipe to make injection.More service is more available to you.

     

     

     

    Injectable Growth Hormone Peptides Eptifibatide Raw Steroid Powders CAS 148031-34-9

    Contact Details
    Guangzhou Kafen Biotech Co.,Ltd

    Contact Person: Albert Gordon

    Send your inquiry directly to us (0 / 3000)